Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00157183 |
Recruitment Status
:
Completed
First Posted
: September 12, 2005
Last Update Posted
: December 5, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Cystic Fibrosis | Device: Nocturnal oxygen , nocturnal bi-level positive pressure ventilation | Phase 1 Phase 2 |
Cystic fibrosis is the commonest life-limiting genetic disorder in the Caucasian population with a median survival of 31 years. Lung disease is responsible for the majority of morbidity and mortality and correlates with declining quality of life. Respiratory failure is the primary cause of death. Daytime respiratory failure (hypoxia with pO2<55 and/or hypercapnia with pCO2>50) is associated with a worse prognosis with a 2-year survival of 50%. Nocturnal respiratory failure (greater than 5% of the night spent with SpO2<90% and/or rise in PtcCO2>10mmHg overnight) is a precursor to the development of daytime respiratory failure. It has been postulated that earlier treatment of respiratory failure may improve outcome and quality of life.
Intervention: Nocturnal O2 and bilevel NIPPV in CF patients with nocturnal respiratory failure, compared to nocturnal placebo (air). Crossover trial utilising patients as their own control.
Aims: (1) To assess the effects of non-invasive ventilation (NIV) and oxygen (O2) therapy on quality of life, hospital admission rate, sleep quality and exercise tolerance in CF patients with NRF (2) To identify a level of severity of NRF where treatment with NIV is effective
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 59 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Masking: | Single |
Primary Purpose: | Treatment |
Official Title: | Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation |
Study Start Date : | March 2003 |
Actual Primary Completion Date : | March 2006 |
Actual Study Completion Date : | March 2006 |

- Quality of life questionnaires:
- CFQoL questionnaire (Gee,Thorax,2000)(a priori chest, physical function, treatment, emotion domains)
- Epworth Sleepiness Scale
- Pittsburgh Sleep Quality Index
- CF Subjective Symptoms Sleep disturbance Questionnaire (CSQ-in house)
- Medical Research Council Dyspnea Scale
- Baseline Dyspnea Index, Transitional Dyspnea Index
- Work or Study status
- Physiological:
- Nocturnal SpO2, nocturnal rise in transcutaneous CO2
- Daytime arterial blood gases (PaCO2, PaO2)
- Admission rate
- Lung function tests (FEV1, FVC, RV/ TLC)
- Modified CF shuttle walk test
- Neurocognitive testing (psychomotor vigilance task, Stroop, Controlled Oral Word Association Test, Trails A and B, digit recall forwards backwards)
- PSG (sleep efficiency, arousal index, % REM sleep, urinary catecholamines)
- Serum cytokines (IL-6, TNF alpha, IL-1 beta)

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
proven diagnosis cystic fibrosis, age 18 years or older, FEV1< 70% predicted normal, clinically stable (no admission or antibiotics last 2 weeks, OR end of admission where further clinical improvement not expected), nocturnal respiratory failure (SpO2<90% for > 10% of night or rise in PtcCO2 > 5 mmHg in REM), daytime hypercapnia (PaCO2> 45 mmHg)
Exclusion Criteria:
Previous home O2 or NIV use, Sedative medications, Cardiac/renal/endocrine/neurological disease likely to compromise ventilatory control

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00157183
Australia, Victoria | |
The Alfred | |
Melbourne, Victoria, Australia, 3181 |
Principal Investigator: | Matthew T Naughton, MD | The Alfred |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Bayside Health |
ClinicalTrials.gov Identifier: | NCT00157183 History of Changes |
Other Study ID Numbers: |
35/03 |
First Posted: | September 12, 2005 Key Record Dates |
Last Update Posted: | December 5, 2013 |
Last Verified: | September 2005 |
Keywords provided by Bayside Health:
cystic fibrosis hypoxia oxygen noninvasive ventilation quality of life |
Additional relevant MeSH terms:
Fibrosis Cystic Fibrosis Pathologic Processes Pancreatic Diseases Digestive System Diseases |
Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Infant, Newborn, Diseases |